US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
biotech · Chronic Peripheral Neuropathy Pain in Diabetics · Diabetic Peripheral Neuropathy · XTLB
XTL BIOPHARMACEUTICALS
XTL BIOPHARMACEUTICALS LTD
XTL BIOPHARMACEUTICALS drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Raanana, USA HQ
1993 Founded
3 Employees
Public company Type
XTLB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Raanana, USA
- Founded
- 1993
- Employees
- 3
- Programs
- 4
- Drugs
- 1
- Patents
- 7
XTL BIOPHARMACEUTICALS pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
XTL BIOPHARMACEUTICALS drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.